LADXLadRx Corporation

About LadRx Corporation (LADX)

LadRx Corporation (LADX) is a Biotechnology company headquartered in Los Angeles, CA, United States whose shares trade over-the-counter on the OTCQB tier.

LadRx is a biopharmaceutical company focused on discovering and developing new therapeutics to treat patients with high unmet needs.

Products and services

LadRx, a biotech company, has developed elegant tumor targeting and release molecules called LADR that are based on small molecular entities (no complex antibodies or nanoparticles) allowing for higher dosing, lower off-target toxicity, and no need for screening patients for presence of antibody targets. Next-gen LADR drug, LADR-7, has been manufactured under GMP and final tox studies completed. LadRx developed aldoxorubicin, a rationally-engineered cytotoxic which delivers well-established anti-cancer agent, doxorubicin, into the tumor. In 2017, out-licensed the rights to aldoxorubicin to ImmunityBio, Inc. (Nasdaq – “IBRX”). In June 2023, LadRx transferred the royalty and milestone rights associated with arimoclomol and aldoxorubicin to XOMA Corporation (NASDAQ: XOMA) (“XOMA”). XOMA consented to the mutual termination of the LadRx-NantCell agreement in order to facilitate the return of the program to LadRx. In parallel, LadRx and XOMA have amended their 2023 Royalty Purchase Agreement to provide XOMA with a low-single-digit synthetic royalty on aldoxorubicin and a mid-single-digit percentage of any economics de. With the return of aldoxorubicin to LadRx, Xoma retains the rights to a small single-digit royalty if LadRx commercializes aldoxorubicin , and a mid-single digit percentage of any licensing/partnering revenue that LadRx receives on aldoxorubicin. LadRx has restarted a process to seek marketing approval under the 505(b)(2) pathway.

LADX key facts

Ticker symbol

LADX

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Los Angeles, CA, United States

Country of incorporation

US

Year of incorporation

1985

Employees

2

Estimated market cap

$816.9K (as of Apr 11, 2025)

Shares outstanding

495,092

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

LadRx Corporation leadership

• Stephen Snowdy — CEO
• John Caloz — CFO
• Greg Marose — IR

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with L